AMPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amphastar Pharmaceuticals, Inc (AMPH) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite some positive technical indicators, the lack of significant positive catalysts, declining financial performance, insider selling, and reduced analyst price targets suggest that holding off on purchasing is a more prudent decision.
The MACD is positive and expanding (0.432), indicating bullish momentum. The RSI is at 73.592, which is in the neutral zone but approaching overbought levels. Moving averages are converging, suggesting indecision in price movement. Key resistance levels are at 20.919 and 21.455, with support at 19.185 and 18.65.
The MACD indicates bullish momentum, and the stock has a 2.78% chance of increasing in the next week.
Insiders are selling heavily, with a 4073.82% increase in selling activity. Financial performance has declined significantly in Q4 2025, with revenue down 1.83% YoY, net income down 35.65% YoY, and EPS down 29.73% YoY. Analysts have lowered price targets, citing slowed momentum and weaker revenue guidance. No recent news or congress trading data to support a positive outlook.
In Q4 2025, revenue dropped to $183.1M (-1.83% YoY), net income dropped to $24.43M (-35.65% YoY), and EPS dropped to $0.52 (-29.73% YoY). Gross margin increased slightly to 46.79% (+0.73% YoY), but overall financial performance shows a negative trend.
Barclays lowered the price target to $23 from $30, maintaining an Equal Weight rating, citing slowed momentum despite recent approvals. Wells Fargo lowered the price target to $30 from $34, maintaining an Overweight rating but highlighting weaker revenue guidance and the importance of AMP-007 for future growth.
